Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction

Amyloid positron-emission-tomography (PET) offers an important research and diagnostic tool for investigating Alzheimer's disease (AD). The majority of amyloid PET studies have used the cerebellum as a reference region, and clinical studies have not accounted for atrophy-based partial volume effects (PVE). Longitudinal studies using cerebellum as reference tissue have revealed only small mean increases and high inter-subject variability in amyloid binding. We aimed to test the effects of different reference regions and PVE-correction (PVEC) on the discriminatory power and longitudinal performance of amyloid PET. We analyzed [(18)F]-AV45 PET and T1-weighted MRI data of 962 subjects at baseline and two-year follow-up data of 258 subjects. Cortical composite volume-of-interest (VOI) values (COMP) for tracer uptake were generated using either full brain atlas VOIs, gray matter segmented VOIs or gray matter segmented VOIs after VOI-based PVEC. Standard-uptake-value ratios (SUVR) were calculated by scaling the COMP values to uptake in cerebellum (SUVRCBL), brainstem (SUVRBST) or white matter (SUVRWM). Mean SUV, SUVR, and changes after PVEC were compared at baseline between diagnostic groups of healthy controls (HC; N=316), mild cognitive impairment (MCI; N=483) and AD (N=163). Receiver operating characteristics (ROC) were calculated for the discriminations between HC, MCI and AD, and expressed as area under the curve (AUC). Finally, the longitudinal [(18)F]-AV45-PET data were used to analyze the impact of quantitation procedures on apparent changes in amyloid load over time. Reference region SUV was most constant between diagnosis groups for the white matter. PVEC led to decreases of COMP-SUV in HC (-18%) and MCI (-10%), but increases in AD (+7%). Highest AUCs were found when using PVEC with white matter scaling for the contrast between HC/AD (0.907) or with brainstem scaling for the contrast between HC/MCI (0.658). Longitudinal increases were greatest in all diagnosis groups with application of PVEC, and inter-subject variability was lowest for the white matter reference. Thus, discriminatory power of [(18)F]-AV45-PET was improved by use of a VOI-based PVEC and white matter or brainstem rather than cerebellum reference region. Detection of longitudinal amyloid increases was optimized with PVEC and white matter reference tissue.

[1]  C. Rowe,et al.  Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults , 2012, Neurology.

[2]  Albert Gjedde,et al.  Subcortical elevation of metabolism in Parkinson's disease — A critical reappraisal in the context of global mean normalization , 2009, NeuroImage.

[3]  P. Pochet A Quantitative Analysis , 2006 .

[4]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[5]  Paul Edison,et al.  Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PIB brain scans? , 2012, NeuroImage.

[6]  Jochen Herms,et al.  Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [18F]-florbetaben PET , 2014, NeuroImage.

[7]  N. Bohnen,et al.  Effectiveness and Safety of 18F-FDG PET in the Evaluation of Dementia: A Review of the Recent Literature , 2012, The Journal of Nuclear Medicine.

[8]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[9]  Keith A. Johnson,et al.  Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging , 2013, Alzheimer's & Dementia.

[10]  L. Thurfjell,et al.  Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Hellmuth Obrig,et al.  Reference Cluster Normalization Improves Detection of Frontotemporal Lobar Degeneration by Means of FDG-PET , 2012, PloS one.

[12]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[13]  Alexander Hammers,et al.  Choice of reference area in studies of Alzheimer's disease using positron emission tomography with fluorodeoxyglucose-F18 , 2008, Psychiatry Research: Neuroimaging.

[14]  Anders M. Dale,et al.  Reliability in multi-site structural MRI studies: Effects of gradient non-linearity correction on phantom and human data , 2006, NeuroImage.

[15]  Rik Ossenkoppele,et al.  Longitudinal Amyloid Imaging Using 11C-PiB: Methodologic Considerations , 2013, The Journal of Nuclear Medicine.

[16]  Arman Rahmim,et al.  Design and Implementation of an Automated Partial Volume Correction in PET: Application to Dopamine Receptor Quantification in the Normal Human Striatum , 2008, Journal of Nuclear Medicine.

[17]  Alexander Hammers,et al.  Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe , 2003, Human brain mapping.

[18]  Kathryn Ziegler-Graham,et al.  Worldwide variation in the doubling time of Alzheimer's disease incidence rates , 2008, Alzheimer's & Dementia.

[19]  M. Chakravarty,et al.  Brain Energy Metabolism and Blood Flow Differences in Healthy Aging , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  J. R.,et al.  Quantitative analysis , 1892, Nature.

[21]  Alan C. Evans,et al.  A nonparametric method for automatic correction of intensity nonuniformity in MRI data , 1998, IEEE Transactions on Medical Imaging.

[22]  R. Boellaard,et al.  Longitudinal amyloid imaging using [11]PIB: Choosing the right method , 2011 .

[23]  I. Buvat,et al.  A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology , 2012, Physics in medicine and biology.

[24]  M. Mintun,et al.  Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects , 2012, The Journal of Nuclear Medicine.

[25]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[26]  R. Coleman,et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.

[27]  Paul Maruff,et al.  Aβ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease , 2013, Alzheimer's & Dementia.

[28]  Sung-Cheng Huang,et al.  Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  A. Evans,et al.  Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  C. Buchpiguel,et al.  Age-Related Metabolic Profiles in Cognitively Healthy Elders: Results from a Voxel-Based [18F]Fluorodeoxyglucose–Positron-Emission Tomography Study with Partial Volume Effects Correction , 2011, American Journal of Neuroradiology.

[31]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[32]  M. Modat,et al.  The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease , 2011, European Journal of Nuclear Medicine and Molecular Imaging.